Sage Therapeutics Shares Fall Premarket After Alzheimer's Setback
Shares of Sage, which closed Monday at $6.72, were recently down 12% to $5.89 in premarket trading. Sage said Tuesday it is ending development of dalzanemdor in Alzheimer's disease after the compound didn't show a statistically significant difference versus placebo on the primary outcome measure of cognitive ability in a Phase 2 study in patients with mild cognitive impairment or mild dementia due to the memory-robbing disease.